许培扬博客分享 http://blog.sciencenet.cn/u/xupeiyang 跟踪国际前沿 服务国内科研

博文

中东呼吸综合征(MERS)临床试验

已有 1727 次阅读 2015-6-7 09:44 |个人分类:传染病学|系统分类:科研笔记

 

1RecruitingRespiratory Virus Hospitalization Study (FLU 003 Plus)
Conditions: Influenza;   Novel Respiratory Virus-1 MERS-CoV;   Novel Respiratory Virus-2 SARS-CoV
Intervention:
2Active, not recruitingAnti-MERS-COV Convalescent Plasma Therapy
Condition: Respiratory Distress Syndrome (& [Hyaline Membrane Disease])
Intervention: Biological: Convalescent plasma
3RecruitingRespiratory Virus Outpatient Study (FLU 002 Plus)
Condition: Influenza and Other Novel Respiratory Viruses
Intervention:
4Enrolling by invitationCollection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases
Condition: Emerging Infectious Diseases
Intervention:
5Completed
Has Results
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated);   Drug: Placebo

https://clinicaltrials.gov/ct2/results?term=middle+east+respiratory+syndrome

 



https://blog.sciencenet.cn/blog-280034-896120.html

上一篇:科学网读者减少的原因
下一篇:中东呼吸综合征(MERS)病毒基因发现
收藏 IP: 114.111.167.*| 热度|

0

该博文允许注册用户评论 请点击登录 评论 (0 个评论)

数据加载中...
扫一扫,分享此博文

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2024-5-19 14:53

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部